QUINAZOLINE BASED EGFR INHIBITORS

(19)

(11)

EP 2 061 469 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 2 (W2 B1)

(48)	Corrigendum issued on:
	26.02.2014 Bulletin 2014/09

(45)	Mention of the grant of the patent:
	05.06.2013 Bulletin 2013/23

(21)	Application number: 07842114.6

(22)	Date of filing: 10.09.2007

(51)

International Patent Classification (IPC):

A61K 31/517^(2006.01)
C07C 211/39^(2006.01)

C07D 239/94^(2006.01)

(86)	International application number:
	PCT/US2007/077974

(87)	International publication number:
	WO 2008/033748 (20.03.2008 Gazette 2008/12)

(54)	QUINAZOLINE BASED EGFR INHIBITORS CHINAZOLIN-BASIERTE EGFR-HEMMER INHIBITEURS D'EGFR À BASE DE QUINAZOLINE

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR
	Designated Extension States:
	AL BA HR MK RS

(30)

Priority:

11.09.2006 US 843644 P
20.03.2007 US 895873 P

(43)	Date of publication of application:
	27.05.2009 Bulletin 2009/22

(73)	Proprietor: Curis, Inc.
	Lexington, MA 02421 (US)

(72)	Inventors:
	QIAN, Changgeng Wayland, MA 01778 (US) CAI, Xiong Belmont, MA 02478 (US)

(74)	Representative: Potter Clarkson LLP
	The Belgrave Centre Talbot Street Nottingham, NG1 5GG Nottingham, NG1 5GG (GB)

(56)

References cited: :

EP-A1- 0 566 226
US-A1- 2004 265 228

WO-A2-2005/097134
US-B1- 6 414 148

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).